Akston Biosciences

Akston Biosciences Overview

Founded 2011
Founded
Status Private
Latest Deal Type Later Stage VC
Latest Deal Amount $7.63M
Latest Deal Amount
Investors 3

Akston Biosciences General Information

Description

Developer of medical insulin devices intended for diabetes prevention. The company's devices can be used in autoimmune Type 1 diabetes prevention, ultra-long-acting insulin therapy and oncology over 24 hours of hypoglycemia-free glucose control in diabetic mice with a single injection, enabling doctors to improve glucose control, reduce complications and eliminate hypoglycemia risk for human and animal health.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • 100 Cummings Center
  • Beverly, MA 01915
  • United States
+1 (978) 000-0000

Akston Biosciences Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Akston Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 11-May-2020 $7.63M 000.00 Completed Generating Revenue
8. Later Stage VC (Series D) 17-May-2018 00.00 000.00 000.00 Completed Generating Revenue
7. Grant 22-Feb-2018 000 00.00 Completed Generating Revenue
6. Angel (individual) 16-Mar-2017 00.00 00.00 Completed Generating Revenue
5. Grant 02-Feb-2017 00000 00.00 Completed Generating Revenue
4. Later Stage VC (Series C) 22-Aug-2016 00.00 00.00 000.00 Completed Generating Revenue
3. Grant 10-Sep-2015 00000 00.00 Completed Generating Revenue
2. Early Stage VC (Series B) 21-May-2015 $1.6M $2.3M 000.00 Completed Generating Revenue
1. Angel (individual) 14-Feb-2013 $700K $700K 00.00 Completed Generating Revenue

Akston Biosciences Cap Table

To view Akston Biosciences‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 000,000 00.000000 00.00 000.00 000.00 00 000.00 0.000
Series C 000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series B 121,934 $0.000001 $1.06 $13.3 $13.3 1x $13.3 7.09%
Series A 139,075 $0.000001 $0.6 $7.5 $7.5 1x $7.5 8.09%

Akston Biosciences Executive Team (4)

Name Title Board Seat Contact Info
Todd Zion Ph.D Founder, Chairman, President & Chief Executive Officer
David Alleva Ph.D Executive Director
Thomas Lancaster Ph.D Vice President, Research & Development and Board Member
James Herriman Vice President, Operations

Akston Biosciences Board Members (4)

Name Representing Role Since
L. Cannon Ph.D Self Board Member 000 0000
Lovick Cannon Akston Biosciences Board Member 000 0000
Robyn Davis Self Board Member 000 0000
Thomas Lancaster Ph.D Akston Biosciences Vice President, Research & Development and Board Member 000 0000

Akston Biosciences Investors (3)

To view Akston Biosciences‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Founders Capital Partners Venture Capital Minority 000 0000 000000 0
The National Institute of Diabetes and Digestive and Kidney Diseases Government 000 0000 000000 0
FundRx Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial